Publicaciones en las que colabora con Miguel Unda Urzaiz (12)

2018

  1. Actualización del papel de la quimioterapia endovesical en el cáncer de vejiga no músculo-invasivo

    Actas Urologicas Espanolas

  2. Review of evidence on handling hazardous drugs and Products in Urology Services; Consensus document between the Spanish Urology Association and the Spanish Society of Health-System Pharmacists

    Biomedical Instrumentation and Technology, Vol. 42, Núm. 5, pp. 212-215

  3. Review of the evidence on handling drugs and hazardous products in Urology Departments. Consensus document between the Spanish Urological Association and the Spanish Society of Hospital Pharmacy

    Actas Urologicas Espanolas, Vol. 42, Núm. 6, pp. 375-380

  4. Revisión de la evidencia sobre el manejo de medicamentos y productos peligrosos en los servicios de Urología; documento de consenso entre la Asociación Española de Urología y la Sociedad Española de Farmacia Hospitalaria

    Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria, Vol. 42, Núm. 5, pp. 212-215

2017

  1. Diagnosis and treatment for clinically localized prostate cancer. Adherence to the European Association of Urology clinical guidelines in a nationwide population-based study – GESCAP group

    Actas Urologicas Espanolas, Vol. 41, Núm. 6, pp. 359-367

2016

  1. Tendencias de tratamiento en el cáncer de próstata clínicamente localizado. Análisis poblacional a nivel nacional: grupo GESCAP

    Actas Urologicas Espanolas, Vol. 40, Núm. 4, pp. 209-216

2015

  1. Maintenance Therapy with 3-monthly Bacillus Calmette-Guérin for 3 Years is Not Superior to Standard Induction Therapy in High-risk Non-muscle-invasive Urothelial Bladder Carcinoma: Final Results of Randomised CUETO Study 98013

    European Urology, Vol. 68, Núm. 2, pp. 256-262

  2. Sequential combination of mitomycin C plus bacillus calmette-guérin (BCG) is more effective but more toxic than BCG alone in patients with non-muscle-invasive bladder cancer in intermediate- and high-risk patients: Final outcome of CUETO 93009, a randomized prospective trial

    European Urology, Vol. 67, Núm. 3, pp. 508-516

2011

  1. The EORTC tables overestimate the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: External validation of the EORTC risk tables

    European Urology, Vol. 60, Núm. 3, pp. 423-430

  2. The EORTC tables overestimate the risk of recurrence and progression in patients with non-muscleinvasive bladder cancer treated with bacillus Calmette-Guérin: External validation of the EORTC risk tables

    International Braz J Urol

2009

  1. Predicting Nonmuscle Invasive Bladder Cancer Recurrence and Progression in Patients Treated With Bacillus Calmette-Guerin: The CUETO Scoring Model

    Journal of Urology, Vol. 182, Núm. 5, pp. 2195-2203

2008

  1. Prognostic Factors in Patients with Non-Muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guérin: Multivariate Analysis of Data from Four Randomized CUETO Trials

    European Urology, Vol. 53, Núm. 5, pp. 992-1002